Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: UCB AES 2018 scientific program

UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership20 scientific presentations illustrate and reinforce dedication to improving patient value in epilepsyData covers licensed medicines, pipeline assets and nonproduct specific topics, providing a platform to share and reinforce UCB’s patient value driven approach for... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.2 notifications referring to situation on 15 and 16 November 2018Threshold crossed: 5%Latest holding: 5.39%Brussels Belgium, 21 November 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Q3 Results

UCB First Nine Months Interim Report 2018:UCB tracking well towards full year financial outlookBrussels Belgium, 30 October 2018 – 7:00 am CET – regulated information –Revenue reached € 3.4 billion 3%; 6% CERStrong growth of UCB’s five main products reached € 2.8 billion 6%; 12% CERR&D update: Cimzia® filed for nonradiographic axial spondyloarthritis nraxSpA in the U.S.; Keppra®... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: ACR bimekizumab

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis PatientsIn the first presentation of longterm data for UCB’s investigational molecule bimekizumab, latebreaking results from the Phase 2b BE ACTIVE study showed promising response rates that increased up to Week 24 and were maintained to Week 48 across disease manifestations in psoriatic... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Topline Results from a Phase 2b Study of Dapirolizumab Pegol in SLE

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus ErythematosusBrussels, Belgium and Cambridge, MA – 23 October 2018, 7:00 AM CEST – Today UCB Euronext Brussels: UCB and Biogen Inc. Nasdaq: BIIB announced topline results from a Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol DZP, an antiCD40L pegylated Fab, in... See more